The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 26, 2019
Filed:
May. 22, 2015
Applicant:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Donald Foster, Attleboro, MA (US);
Brian Bettencourt, Groton, MA (US);
Klaus Charisse, Acton, MA (US);
Gregory Hinkle, Plymouth, MA (US);
Satyanarayana Kuchimanchi, Acton, MA (US);
Martin Maier, Belmont, MA (US);
Stuart Milstein, Arlington, MA (US);
Assignee:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/11 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 47/54 (2017.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 45/06 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/343 (2013.01); C12N 2310/351 (2013.01); C12N 2320/32 (2013.01); C12N 2320/51 (2013.01);
Abstract
The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.